Images List Premium Download Classic

Pharmaceutically Acceptable Salts

Pharmaceutically Acceptable Salts-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Compounds useful in the synthesis of halichondrin b analogs
Eisai R&d Management Co., Ltd.
June 14, 2018 - N°20180162885

In general, the invention features compounds useful for the synthesis of analogs of halichondrin b, such as eribulin or pharmaceutically acceptable salts thereof, e.g., eribulin mesylate. Exemplary compounds are of formula (i), (ii), or (iii):.
Janus kinase inhibitor
Wuxi Fortune Pharmaceutical Co., Ltd
June 14, 2018 - N°20180162879

Disclosed are a series of janus kinase inhibitors, and particularly disclosed are a compound or pharmaceutically acceptable salts thereof of formula (i) and use thereof in the preparation of drugs for treating janus kinase (jak)-related diseases.. .
Benzenesulfonamide compounds and their use as therapeutic agents
Xenon Pharmaceuticals Inc.
June 14, 2018 - N°20180162868

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.. .
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pdd and bpd compounds
Femtogenix Limited
June 14, 2018 - N°20180162855

The invention relates to pyrridinobenzodiazepines (pdds) comprising three fused 6-7-6-membered rings and to benzopyrridodiazecines (bpds) comprising three fused 6-8-6-membered rings and, in particular, to pdd or bpd dimers linked together or pdd and bpd monomers linked to aromatic groups, and pharmaceutically acceptable salts thereof, which are useful as medicaments, such as anti-proliferative agents. Pdds and bpds ...
Compounds for the modulation of myc activity
Syros Pharmaceuticals, Inc.
June 14, 2018 - N°20180162851

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, ...
Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
Epizyme, Inc.
June 14, 2018 - N°20180162847

Described herein are compounds of formula (a), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting prmt5 activity.
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Inhibitors of leukotriene a4 hydrolase
June 14, 2018 - N°20180162836

Where r1a, r3, y, and z are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, n-oxides or prodrugs thereof; which are leukotriene a4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are ...
Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
Je Il Pharmaceutical Co., Ltd.
June 14, 2018 - N°20180162834

The present invention relates to novel tricyclic derivative compounds, and more specifically to tricyclic derivative compounds, optical isomers thereof, racemates thereof, or pharmaceutically acceptable salts thereof, which have excellent activity against parp-1, tankyrase-1 or tankyrase-2. The tricyclic derivative compounds, optical isomers thereof, racemates thereof or pharmaceutically acceptable salts thereof according to the present invention have inhibitory activity against parp-1, tankyrase-1, ...
2-(2,4,5-substituted-anilino)pyrimidine compounds
Astrazeneca Ab
June 14, 2018 - N°20180162832

The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the l858r activating mutant, the exon19 deletion activating mutant and the t790m resistance mutant). Such compounds ...
Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
Viiv Healthcare Uk (no.5) Limited
June 14, 2018 - N°20180162831

Disclosed are compounds of formula i, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting hiv integrase and treating those infected with hiv or aids.. .
Phthalazinones and isoquinolinones as rock inhibitors
June 14, 2018 - N°20180162823

Or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective rock inhibitors.
Factor xia macrocycles with novel p1 groups
June 14, 2018 - N°20180162821

Or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor xia inhibitors or dual inhibitors of fxia and plasma kallikrein.
Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase
June 14, 2018 - N°20180162804

Where r1a, r1b, r1c, r1d, r1e, r3, r4a, r4b, r4c, r4d, r6, r7, and r8 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, n-oxides or prodrugs thereof; which are leukotriene a4 hydrolase inhibitors and therefore useful in treating inflammatory ...
Pharmaceutically Acceptable Salts Patent Pack
Download 794+ patent application PDFs
Pharmaceutically Acceptable Salts Patent Applications
Download 794+ Pharmaceutically Acceptable Salts-related PDFs
For professional research & prior art discovery
inventor
  • 794+ full patent PDF documents of Pharmaceutically Acceptable Salts-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Ship1 modulators and methods related thereto
June 14, 2018 - N°20180161324

N, r1, r4a, r4b, r5, r7 and r8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as ship1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from ship1 modulation.
Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
Takeda Pharmaceuticals U.s.a., Inc.
June 14, 2018 - N°20180161321

New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.. .
Oral solution comprising atomoxetine hydrochloride and methods thereof
Taho Pharmaceuticals Ltd.
June 14, 2018 - N°20180161289

Disclosed herein is an oral pharmaceutical composition in the form of an aqueous solution of atomoxetine as an active ingredient. The aqueous solution of atomoxetine comprises a taste-masked liquid carrier comprising peppermint, orange flavor and a viscosity agent.
Methods and compositions for the treatment of seizure-related disorders
Adamas Pharmaceuticals, Inc.
June 14, 2018 - N°20180161282

Compositions and methods are provided for administering a pharmaceutical composition to a human patient. Compositions are administered to a human patient orally, once daily, at a therapeutically effective dose.
Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
June 07, 2018 - N°20180155365

And pharmaceutically acceptable salts or prodrug thereof, wherein a, x, r1, r2, r3 and r7 are as defined herein. The present invention also relates to compositions comprising at least one tetracyclic heterocycle compound, and methods of using the tetracyclic heterocycle compounds for treating or preventing hiv infection in a subject..
Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
Laurus Labs Limited
June 07, 2018 - N°20180155364

The present invention relates to a novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof using novel intermediates.. .
Mcl-1 inhibitors and methods of use thereof
June 07, 2018 - N°20180155362

And enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions..
Crystalline forms of a bruton's tyrosine kinase inhibitor
Pharmacyclics Llc
June 07, 2018 - N°20180155352

Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other ...
Loading